Published in Br J Cancer on April 22, 2003
Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res (2008) 2.67
A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer (2006) 2.57
Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol (2008) 2.04
Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. Ann Oncol (2013) 1.92
A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Invest New Drugs (2011) 1.49
Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer (2006) 1.41
Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study. Invest New Drugs (2005) 1.34
Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options? World J Gastroenterol (2014) 1.13
Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. Br J Cancer (2006) 1.02
From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates. Invest New Drugs (2006) 0.97
Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer. Invest New Drugs (2009) 0.96
Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma. Am J Clin Oncol (2011) 0.94
A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer. Transl Oncol (2010) 0.90
FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts. World J Gastroenterol (2012) 0.87
Phase II study of palliative S-1 in combination with cisplatin as second-line chemotherapy for gemcitabine-refractory pancreatic cancer patients. Oncol Lett (2012) 0.87
Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity. Exp Hematol Oncol (2015) 0.85
Phase I trials in patients with relapsed, advanced upper gastrointestinal carcinomas: experience in a specialist unit. Gastric Cancer (2014) 0.80
Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT). BMC Cancer (2016) 0.80
A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer. Br J Cancer (2007) 0.79
Pancreatic cancer: New hopes after first line treatment. World J Gastrointest Oncol (2016) 0.78
Systemic therapy for metastatic pancreatic adenocarcinoma. Ther Adv Med Oncol (2010) 0.78
Treatment of pancreatic cancer: what can we really predict today? Cancers (Basel) (2011) 0.76
Modified irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): a single-institution experience. Med Oncol (2016) 0.75
Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinoma. Oncol Lett (2017) 0.75
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol (1997) 29.02
Reporting results of cancer treatment. Cancer (1981) 28.83
Optimal two-stage designs for phase II clinical trials. Control Clin Trials (1989) 21.03
Cancer statistics, 1996. CA Cancer J Clin (1996) 6.85
Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol (1996) 4.00
Chemotherapy of adenocarcinoma of the pancreas. Semin Oncol (1996) 1.59
Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg (1994) 1.57
Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer. J Clin Oncol (2001) 1.50
Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs (2000) 1.37
Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. J Clin Oncol (2002) 1.27
Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer. Oncologist (2001) 1.15
Phase II trial of ZD1694 (Tomudex) in patients with advanced pancreatic cancer. Invest New Drugs (1996) 1.05
Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro. Clin Cancer Res (1998) 0.90
A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma. Cancer (2000) 0.89
A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer. Int J Oncol (1999) 0.89
Gemcitabine-based combination treatment of pancreatic cancer. Semin Oncol (2002) 0.88
Irinotecan(Campto R): efficacy as third/forth line therapy in advanced pancreatic cancer. Anticancer Res (2001) 0.86
Phase I study of irinotecan and raltitrexed in patients with advanced gastrointestinal tract adenocarcinoma. Br J Cancer (2000) 0.85
Raltitrexed: current clinical status and future directions. Ann Oncol (2002) 0.85
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol (2012) 5.32
Interaction of rifamycin with bacterial RNA polymerase. Proc Natl Acad Sci U S A (1968) 4.07
Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol (2002) 3.91
Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ (1993) 3.26
Sharing of virulence-associated properties at the phenotypic and genetic levels between enteropathogenic Escherichia coli and Hafnia alvei. J Med Microbiol (1992) 3.03
T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia (2005) 2.73
The low-affinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells. Biochem J (2000) 2.59
Transformation of human lymphocytes: inhibition by homologous alpha globulin. Science (1968) 2.55
Hafnia alvei, a probable cause of diarrhea in humans. Infect Immun (1991) 2.55
Plasmid-mediated resistance to nalidixic acid in Shigella dysenteriae type 1. Lancet (1987) 2.32
Import of mitochondrial carriers mediated by essential proteins of the intermembrane space. Science (1998) 2.27
Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma. Leukemia (2006) 2.24
Early prediction of individual outcome after cardiopulmonary resuscitation. Lancet (1993) 2.21
FAS-induced apoptosis is mediated via a ceramide-initiated RAS signaling pathway. Immunity (1995) 2.19
Cloning and characterization of a putative human serine/threonine protein kinase transcriptionally modified during anisotonic and isotonic alterations of cell volume. Proc Natl Acad Sci U S A (1997) 2.14
Culture from mouse bone marrow of a subclass of mast cells possessing a distinct chondroitin sulfate proteoglycan with glycosaminoglycans rich in N-acetylgalactosamine-4,6-disulfate. J Biol Chem (1982) 2.13
Irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin. J Natl Cancer Inst (1998) 2.12
Mutations in GJB6 cause nonsyndromic autosomal dominant deafness at DFNA3 locus. Nat Genet (1999) 2.05
Templated nucleotide addition and immunoglobulin JH-gene utilization in t(11;14) junctions: implications for the mechanism of translocation and the origin of mantle cell lymphoma. Cancer Res (2001) 1.98
EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut (2011) 1.96
Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Ann Oncol (2004) 1.95
Determination of the primary structures of 16 asialo-carbohydrate units derived from human plasma alpha 1-acid glycoprotein by 360-MHZ 1H NMR spectroscopy and permethylation analysis. Biochemistry (1978) 1.92
Cholera epidemics in Bangladesh: 1985-1991. J Diarrhoeal Dis Res (1992) 1.92
Tn1721-encoded tetracycline resistance: mapping of structural and regulatory genes mediating resistance. J Bacteriol (1983) 1.92
Enteropathogens associated with acute and persistent diarrhea in Bangladeshi children less than 5 years of age. J Infect Dis (1992) 1.91
Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol (1997) 1.91
XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer (2011) 1.90
Size of surgical margin does not influence recurrence rates after curative liver resection for colorectal cancer liver metastases. Br J Surg (2007) 1.85
Plasmid-mediated uptake and metabolism of sucrose by Escherichia coli K-12. J Bacteriol (1982) 1.84
Anaerobic dechlorination and degradation of hexachlorocyclohexane isomers by anaerobic and facultative anaerobic bacteria. Arch Microbiol (1977) 1.83
Survival of classic cholera in Bangladesh. Lancet (1991) 1.83
The effect of immunoregulatory globulin (IRA) upon lymphocytes in vitro. J Immunol (1972) 1.79
CD95/CD95 ligand interactions on epithelial cells in host defense to Pseudomonas aeruginosa. Science (2000) 1.77
Heterologous repressor-operator recognition among four classes of tetracycline resistance determinants. J Bacteriol (1985) 1.76
Synthesis of a muscarinic receptor antagonist via a diastereoselective Michael reaction, selective deoxyfluorination and aromatic metal-halogen exchange reaction. J Org Chem (2001) 1.75
CTnscr94, a conjugative transposon found in enterobacteria. J Bacteriol (1997) 1.70
Nucleotide sequences and operon structure of plasmid-borne genes mediating uptake and utilization of raffinose in Escherichia coli. J Bacteriol (1989) 1.70
Isolation of an immunosuppressive peptide fraction from human plasma. J Immunol (1973) 1.70
Decomposition of 14C-labelled lignin and phenols by a Nocardia sp. Arch Microbiol (1977) 1.69
Extracellular K+ and intracellular pH allosterically regulate renal Kir1.1 channels. J Biol Chem (1996) 1.68
Influence of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone on serologic parameters and clinical course in lymphoma patients with autoimmune diseases. Ann Oncol (2007) 1.67
Screening for lignin degrading bacteria by means of 14C-labelled lignins. Arch Microbiol (1978) 1.65
Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol (2001) 1.64
Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. Ann Oncol (2003) 1.62
Repulsively bound atom pairs in an optical lattice. Nature (2006) 1.62
Active unfolding of precursor proteins during mitochondrial protein import. EMBO J (1997) 1.62
Function and structure of heterodimeric amino acid transporters. Am J Physiol Cell Physiol (2001) 1.60
Cyclophilin catalyzes protein folding in yeast mitochondria. Proc Natl Acad Sci U S A (1995) 1.60
Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites. Leukemia (2004) 1.59
An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol (2007) 1.58
Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res (2001) 1.57
Tim9p, an essential partner subunit of Tim10p for the import of mitochondrial carrier proteins. EMBO J (1998) 1.55
'Blind' antibiotic treatment targeting Chlamydia is not effective in patients with MALT lymphoma of the ocular adnexa. Ann Oncol (2006) 1.54
CD66-mediated phagocytosis of Opa52 Neisseria gonorrhoeae requires a Src-like tyrosine kinase- and Rac1-dependent signalling pathway. EMBO J (1998) 1.53
Cell volume in the regulation of hepatic function: a mechanism for metabolic control. Biochim Biophys Acta (1991) 1.51
Fas- or ceramide-induced apoptosis is mediated by a Rac1-regulated activation of Jun N-terminal kinase/p38 kinases and GADD153. J Biol Chem (1997) 1.51
The astroglial ASCT2 amino acid transporter as a mediator of glutamine efflux. J Neurochem (1999) 1.50
Association between Helicobacter pylori infection and pancreatic cancer. Oncology (1998) 1.49
Similar metabolic responses to standardized total parenteral nutrition of septic and nonseptic critically ill patients. Am J Clin Nutr (2001) 1.49
Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol (2004) 1.49
Acidic sphingomyelinase mediates entry of N. gonorrhoeae into nonphagocytic cells. Cell (1997) 1.47
Competitive blockade of lymphocyte stimulation by a serum immuno-regulatory alpha globulin (IRA). Transplant Proc (1969) 1.47
Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol (2004) 1.46
Chemical and physicochemical studies on the mineral deposits of the human atherosclerotic aorta. Atherosclerosis (1980) 1.46
Role of N-linked glycosylation in rat renal Na/Pi-cotransport. J Biol Chem (1994) 1.46
Synaptic vesicles: selective depletion in crayfish excitatory and inhibitory axons. Science (1972) 1.44
Raffinose metabolism in Escherichia coli K12. Purification and properties of a new alpha-galactosidase specified by a transmissible plasmid. Eur J Biochem (1976) 1.44
Modulation of Neisseria porin (PorB) by cytosolic ATP/GTP of target cells: parallels between pathogen accommodation and mitochondrial endosymbiosis. Cell (1996) 1.44
Changing pattern of resistant Shiga bacillus (Shigella dysenteriae type 1) and Shigella flexneri in Bangladesh. J Infect Dis (1985) 1.43
Inheritance of human alpha-1-acid glycoprotein (orosomucoid) variants. J Clin Invest (1969) 1.43
Fat elimination in acute renal failure: long-chain vs medium-chain triglycerides. Am J Clin Nutr (1992) 1.42
Immunosuppression by human plasma alpha 1-acid glycoprotein: importance of the carbohydrate moiety. Proc Natl Acad Sci U S A (1980) 1.41
Second-line treatment of advanced gastric cancer with oxaliplatin plus raltitrexed. Onkologie (2003) 1.41
[Cardiovascular diseases caused by unemployment? An analysis from the viewpoint of social medicine]. Wien Klin Wochenschr (1997) 1.40
Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Lett (1996) 1.40
Three new restriction endonucleases MaeI, MaeII and MaeIII from Methanococcus aeolicus. Nucleic Acids Res (1984) 1.39
The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes. Br J Pharmacol (1997) 1.38
Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients. Onkologie (2003) 1.38
Acute pulmonary toxicity associated with high-dose vinorelbine and mitomycin C. Ann Oncol (1996) 1.38